Five-year Local Control in a Phase II Study of Hypofractionated Intensity Modulated Radiation Therapy With an Incorporated Boost for Early Stage Breast Cancer

被引:33
|
作者
Freedman, Gary M. [1 ]
Anderson, Penny R. [2 ]
Bleicher, Richard J. [4 ]
Litwin, Samuel [3 ]
Li, Tianyu [3 ]
Swaby, Ramona F. [5 ]
Ma, Chang-Ming Charlie [2 ]
Li, Jinsheng [2 ]
Sigurdson, Elin R. [4 ]
Watkins-Bruner, Deborah [6 ]
Morrow, Monica [7 ]
Goldstein, Lori J. [5 ]
机构
[1] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA
[2] Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA
[3] Fox Chase Canc Ctr, Dept Biostat, Philadelphia, PA 19111 USA
[4] Fox Chase Canc Ctr, Dept Surg Oncol, Philadelphia, PA 19111 USA
[5] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA
[6] Emory Univ, Sch Nursing, Atlanta, GA 30322 USA
[7] Mem Sloan Kettering Canc Ctr, Dept Surg Oncol, New York, NY 10021 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2012年 / 84卷 / 04期
关键词
Breast boost; Breast cancer; Hypofractionation; IMRT; Radiation therapy; CONSERVING SURGICAL-PROCEDURES; QUALITY-OF-LIFE; RANDOMIZED-TRIAL; RADIOTHERAPY; WOMEN; IRRADIATION; SURGERY; FORM; RT;
D O I
10.1016/j.ijrobp.2012.01.091
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Conventional radiation fractionation of 1.8-2 Gy per day for early stage breast cancer requires daily treatment for 6-7 weeks. We report the 5-year results of a phase II study of intensity modulated radiation therapy (IMRT), hypofractionation, and incorporated boost that shortened treatment time to 4 weeks. Methods and Materials: The study design was phase II with a planned accrual of 75 patients. Eligibility included patients aged >= 18 years, Tis-T2, stage 0-II, and breast conservation. Photon IMRT and an incorporated boost was used, and the whole breast received 2.25 Gy per fraction for a total of 45 Gy, and the tumor bed received 2.8 Gy per fraction for a total of 56 Gy in 20 treatments over 4 weeks. Patients were followed every 6 months for 5 years. Results: Seventy-five patients were treated from December 2003 to November 2005. The median follow-up was 69 months. Median age was 52 years (range, 31-81). Median tumor size was 1.4 cm (range, 0.1-3.5). Eighty percent of tumors were node negative; 93% of patients had negative margins, and 7% of patients had close (>0 and <2 mm) margins; 76% of cancers were invasive ductal type: 15% were ductal carcinoma in situ, 5% were lobular, and 4% were other histology types. Twenty-nine percent of patients 29% had grade 3 carcinoma, and 20% of patients had extensive in situ carcinoma; 11% of patients received chemotherapy, 36% received endocrine therapy, 33% received both, and 20% received neither. There were 3 instances of local recurrence for a 5-year actuarial rate of 2.7%. Conclusions: This 4-week course of hypofractionated radiation with incorporated boost was associated with excellent local control, comparable to historical results of 6-7 weeks of conventional whole-breast fractionation with sequential boost. (C) 2012 Elsevier Inc.
引用
收藏
页码:888 / 893
页数:6
相关论文
共 50 条
  • [31] Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results
    De Rose, Fiorenza
    Fogliata, Antonella
    Franceschini, Davide
    Navarria, Piera
    Villa, Elisa
    Iftode, Cristina
    D'Agostino, Giuseppe
    Cozzi, Luca
    Lobefalo, Francesca
    Mancosu, Pietro
    Tomatis, Stefano
    Scorsetti, Marta
    RADIATION ONCOLOGY, 2016, 11
  • [32] Five-year survival outcomes of intensity-modulated radiotherapy with simultaneous integrated boost (IMRT-SIB) using forward IMRT or Tomotherapy for breast cancer
    Lee, Hsin-Hua
    Chen, Chien-Hung
    Luo, Kuei-Hau
    Chuang, Hung-Yi
    Huang, Chih-Jen
    Cheng, Yuan-Kai
    Chen, Frank
    Kuo, Shih-Hsun
    Huang, Ming-Yii
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [33] Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme
    Jastaniyah, Noha
    Murtha, Albert
    Pervez, Nadeem
    Le, Duc
    Roa, Wilson
    Patel, Samir
    Mackenzie, Marc
    Fulton, Dorcas
    Field, Colin
    Ghosh, Sunita
    Fallone, Gino
    Abdulkarim, Bassam
    RADIATION ONCOLOGY, 2013, 8
  • [34] A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity Modulated Radiation Therapy in Early-Stage Prostate Cancer Patients
    Vapiwala, Neha
    Wong, J. Karen
    Handorf, Elizabeth
    Paly, Jonathan
    Grewal, Amardeep
    Tendulkar, Rahul
    Godfrey, Devon
    Carpenter, David
    Mendenhall, Nancy P.
    Henderson, Randal H.
    Stish, Bradley J.
    Vargas, Carlos
    Salama, Joseph K.
    Davis, Brian J.
    Horwitz, Eric M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 110 (04): : 1082 - 1089
  • [35] Highly hypofractionated intensity-modulated radiation therapy for nonmetastatic prostate cancer with a simultaneous integrated boost to intraprostatic lesions: a planning study
    Ashida, Ryo
    Nakamura, Kiyonao
    Aizawa, Rihito
    Iramina, Hiraku
    Takayama, Kenji
    Nakamura, Mitsuhiro
    Mizowaki, Takashi
    JAPANESE JOURNAL OF RADIOLOGY, 2022, 40 (02) : 210 - 218
  • [36] Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments
    Marta Scorsetti
    Filippo Alongi
    Antonella Fogliata
    Sara Pentimalli
    Pierina Navarria
    Francesca Lobefalo
    Carlos Garcia-Etienne
    Alessandro Clivio
    Luca Cozzi
    Pietro Mancosu
    Giorgia Nicolini
    Eugenio Vanetti
    Marco Eboli
    Carlo Rossetti
    Arianna Rubino
    Andrea Sagona
    Stefano Arcangeli
    Wolfgang Gatzemeier
    Giovanna Masci
    Rosalba Torrisi
    Alberto Testori
    Marco Alloisio
    Armando Santoro
    Corrado Tinterri
    Radiation Oncology, 7
  • [37] Intensity-modulated and hypofractionated simultaneous integrated boost adjuvant breast radiation employing statics ports of tomotherapy (TomoDirect): a prospective phase II trial
    Pierfrancesco Franco
    Michele Zeverino
    Fernanda Migliaccio
    Domenico Cante
    Piera Sciacero
    Valeria Casanova Borca
    Paolo Torielli
    Cecilia Arrichiello
    Giuseppe Girelli
    Maria Rosa La Porta
    Santi Tofani
    Gianmauro Numico
    Umberto Ricardi
    Journal of Cancer Research and Clinical Oncology, 2014, 140 : 167 - 177
  • [38] Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity
    Paydar, Ima
    Pepin, Abigail
    Cyr, Robyn A.
    King, Joseph
    Yung, Thomas M.
    Bullock, ElizabethG.
    Lei, Siyuan
    Satinsky, Andrew
    Harter, K. William
    Suy, Simeng
    Dritschilo, Anatoly
    Lynch, John H.
    Kole, Thomas P.
    Collins, Sean P.
    FRONTIERS IN ONCOLOGY, 2017, 7
  • [39] Cost-effectiveness of intraoperative radiation therapy versus intensity-modulated radiation therapy for the treatment of early breast cancer: a disinvestment analysis
    Munoz-Montecinos, Carlos
    Gonzalez-Browne, Catalina
    Maza, Felipe
    Carreno-Leiton, Diego
    Gonzalez, Pablo
    Chahuan, Badir
    Quirland, Camila
    BMC HEALTH SERVICES RESEARCH, 2024, 24 (01)
  • [40] A dosimetry study precisely outlining the heart substructure of left breast cancer patients using intensity-modulated radiation therapy
    Fan, Ling-li
    Luo, Yang-kun
    Xu, Jing-hui
    He, Ling
    Wang, Jie
    Du, Xiao-bo
    JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2014, 15 (05): : 265 - 274